Stay updated with breaking news from Biosimilar Working Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The "interchangeable" designation has created confusion around the difference between biosimilars designated as interchangeable and those that are not.
An FDA workshop featuring regulators from around the world provided the regulatory perspective on how each government determines whether a biosimilar is clinically equivalent to their reference product, highlighting the science behind their development guidelines.
/PRNewswire/ -- The Accreditation Council for Medical Affairs (ACMA) is launching a new Board Certification program focused on biologics and biosimilars. This...